&Nbsp Was Reported On The Eve Of The Listing Of H Shares, And The Stall Of The Three Largest Pharmaceutical Company Stalled.

In May 16th, it was the end of Shanghai medicine.

At this point, it is only two days from Shanghai medical H-share listing.

In May 20th, Shanghai's medicine was finally listed in Hong Kong under the "siege" of the giant. The opening price was HK $23.25, the highest price was HK $23.35, and traded at HK $1 billion 880 million throughout the day, with a turnover rate of 11.16%.

The closing price was HK $23, which was barely flat with the IPO issue price and fell to HK $22.85 once in session.

15.06 times oversubscribed is far away from the 570.11 times subscription of IPO in 2009.

"This situation is really rare in my mind, and it has made such a big difference that it was very rare to go directly to the Hong Kong stock exchange a few days before listing, which is equivalent to a direct stab in the medicine.

What is the reason why medicine is enclosed?

Pre market reporting letter

"We should be more satisfied with the results of the issue," he told reporters. "We have clarified the announcement of the Huayuan incident, which has no impact on our listing."

At present, Huayuan's affairs are mainly based on announcements. Now we can't give more opinions.

However, Huayuan pharmaceuticals, the initiator of the "report gate", avoided talking about it, and its secretaries did not feel well about the times weekly reporter: "I am not clear about this matter. I do not know anything about the report door. We are not easy to make any comments."

In May 16th, the Hongkong stock exchange and

One stone stirred up thousands of waves. After Shanghai media reported, Shanghai Medicine issued a Clarification Announcement on May 18th, saying: "the new pioneer of the New Zealand is not the business and assets of the group, nor does the products involved belong to the group's products.

If a listed company suffers any economic loss due to judicial proceedings, it will be borne by the pharmaceutical group. The incident is not related to the listed company, and will not adversely affect the operation.

However, second days after the incident, Shanghai medical A shares fell for three consecutive years. After the completion of H share market, it fell by 1.39% in May 23rd. At the time of the press release, Shanghai pharmaceutical A shares closed at 24 yuan on the 24 day, or 0.94%.

Immediately, Li Li, director of the Ministry of justice of Anhui Huayuan County, published a blog entitled "here is Shanghai", detailing the ins and outs of the reporting incidents. The article pointed out that in March 2nd this year, the national development and Reform Commission lowered the retail price of cefotaxime from the original 99.5 yuan to 53.4 yuan. After the price of similar products in China has been lowered, the new pioneers wanted to find another dealer instead of paying attention to the price reduction of Huayuan company, resulting in the company losing competitiveness and freezing several bank accounts. The frozen capital has exceeded 96 million yuan, causing huge losses to Anhui Huayuan.

Li Li said: at present, the new pioneers are still in touch with our company, and both sides have been looking for a suitable settlement plan.

However, due to the outbreak of the scandal in the 4 days before the listing of H-share, the focus of the market is no longer on the drugs and Huarun's two companies.

"My first reaction at that time was that Huarun really burned, and some could not carry it.

Whether Huarun is jealous or anxious, it is a bit of a bear.

Although both sides are now talking about reconciliation, the key is that the timing is too clever to send directly to the HKEx, which is a bit ruthless.

The industry insiders told the times weekly reporter.

"From the close of the first day of the drug H-share listing, it must have been affected by the reported events. In fact, whether it is Huayuan or Huarun, it will be a great loss to both sides if they are so noisy."

An Bang consulting pharmaceutical industry analyst Bian Chengguang told the times weekly reporter.